These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23051697)

  • 81. Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys.
    Wong MC; John GK; Hirai HW; Lam TY; Luk AK; Ching JY; Ng SS; Chan FK; Griffiths SM; Sung JJ
    Cancer Causes Control; 2012 Sep; 23(9):1541-8. PubMed ID: 22836914
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Esophageal Squamous Cell Carcinoma Patients Have an Increased Risk of Coexisting Colorectal Neoplasms.
    Baeg MK; Choi MG; Jung YD; Ko SH; Lim CH; Kim HH; Kim JS; Cho YK; Park JM; Lee IS; Kim SW
    Gut Liver; 2016 Jan; 10(1):76-82. PubMed ID: 25963088
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Follow-up of patients undergoing both semiquantitated immunochemical fecal occult blood and colonoscopy examinations.
    Rozen P; Liphshitz I; Barchana M
    Eur J Cancer Prev; 2012 May; 21(3):247-53. PubMed ID: 21955798
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ethnic and sex disparities in colorectal neoplasia among Hispanic patients undergoing screening colonoscopy.
    Lathroum L; Ramos-Mercado F; Hernandez-Marrero J; Villafaña M; Cruz-Correa M
    Clin Gastroenterol Hepatol; 2012 Sep; 10(9):997-1001. PubMed ID: 22542749
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test.
    Tsuji Y; Gunji T; Sato H; Ono A; Ito T; Ohata K; Yamamichi N; Fujishiro M; Matsuhashi N; Koike K
    Dig Endosc; 2014 May; 26(3):424-9. PubMed ID: 24325675
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
    Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
    Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Incidence and recurrence rates of colorectal adenomas in first-degree asymptomatic relatives of patients with colon cancer.
    Fossi S; Bazzoli F; Ricciardiello L; Nicolini G; Zagari RM; Pozzato P; Palli D; Roda E
    Am J Gastroenterol; 2001 May; 96(5):1601-4. PubMed ID: 11374706
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Optimizing sampling device for the fecal immunochemical test increases colonoscopy yields in colorectal cancer screening.
    Huang Y; Li Q; Ge W; Hu Y; Cai S; Yuan Y; Zhang S; Zheng S
    Eur J Cancer Prev; 2016 Mar; 25(2):115-22. PubMed ID: 25768975
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
    Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
    Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors.
    Cottet V; Pariente A; Nalet B; Lafon J; Milan C; Olschwang S; Bonaiti-Pellié C; Faivre J; Bonithon-Kopp C;
    Gastroenterology; 2007 Oct; 133(4):1086-92. PubMed ID: 17919484
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Risk factors for advanced colorectal adenomas: a pooled analysis.
    Terry MB; Neugut AI; Bostick RM; Sandler RS; Haile RW; Jacobson JS; Fenoglio-Preiser CM; Potter JD
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):622-9. PubMed ID: 12101109
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test.
    Chiu HM; Lee YC; Tu CH; Chen CC; Tseng PH; Liang JT; Shun CT; Lin JT; Wu MS
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):832-8.e1-2. PubMed ID: 23376002
    [TBL] [Abstract][Full Text] [Related]  

  • 93. DIAGNOSTIC ACCURACY OF ONE SAMPLE OR TWO SAMPLES QUANTITATIVE FECAL IMMUNOCHEMICAL TESTS FOR INTESTINAL NEOPLASIA DETECTION.
    Mattar R; Marques SB; Minata MK; Silva-Etto JMKD; Sakai P; DE Moura EGH
    Arq Gastroenterol; 2020; 57(3):316-322. PubMed ID: 32935747
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Fecal occult blood testing: a false sense of security?
    Schnell T; Aranha GV; Sontag SJ; Tode R; Reid S; Chejfec G; Karpf J; Levine G
    Surgery; 1994 Oct; 116(4):798-802; discussion 802-3. PubMed ID: 7940181
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prevalence of synchronous colorectal neoplasms in surgically treated gastric cancer patients and significance of screening colonoscopy.
    Suzuki A; Koide N; Takeuchi D; Okumura M; Ishizone S; Suga T; Miyagawa S
    Dig Endosc; 2014 May; 26(3):396-402. PubMed ID: 23967873
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Faecal immunochemical test mitigates risk of delayed colonoscopy in people with elevated risk of colorectal neoplasia.
    Wassie MM; Young GP; Cock C; Bampton P; Winter JM; Simpson K; Saluja H; Chuang A; Fraser RJ; Symonds EL
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1067-1075. PubMed ID: 35261071
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects.
    Yeoh KG; Ho KY; Chiu HM; Zhu F; Ching JY; Wu DC; Matsuda T; Byeon JS; Lee SK; Goh KL; Sollano J; Rerknimitr R; Leong R; Tsoi K; Lin JT; Sung JJ;
    Gut; 2011 Sep; 60(9):1236-41. PubMed ID: 21402615
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Colorectal cancer screening among first-degree relatives of colorectal cancer patients: benefits and barriers.
    Mack LA; Cook LS; Temple WJ; Carlson LE; Hilsden RJ; Paolucci EO
    Ann Surg Oncol; 2009 Aug; 16(8):2092-100. PubMed ID: 19479307
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
    Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.